Influence of Treatment of Tourette Syndrome with Δ9-Tetrahydrocannabinol (Δ9-THC) on Neuropsychological Performance

K. R. Müller-Vahl; A. Koblenz; M. Jöbges; H. Kolbe; H. M. Emrich; U. Schneider

doi:10.1055/s-2001-15191

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2001; 34(1): 19-24
DOI: 10.1055/s-2001-15191

Original Paper

Influence of Treatment of Tourette Syndrome with Δ⁹-Tetrahydrocannabinol (Δ⁹-THC) on Neuropsychological Performance

K. R. Müller-Vahl¹ , A. Koblenz¹ , M. Jöbges² , H. Kolbe² , H. M. Emrich¹ , U. Schneider¹

¹Department of Clinical Psychiatry and Psychotherapy
²Department of Neurology
Medical School Hannover, Germany

Abstract

Previous studies have suggested that marijuana (cannabis sativa) and delta-9-tetrahydrocannabinol (Δ⁹-THC), the major psychoactive ingredient of marijuana, are effective in the therapy of tics and associated behavioral disorders in Tourette Syndrome (TS). Because there is also evidence that cannabis sativa may cause cognitive impairment in healthy users, we performed a randomized double-blind placebo-controlled crossover trial for Δ⁹-THC in 12 adult TS patients to investigate whether treatment of TS with a single dose of Δ⁹-THC at 5.0 to 10.0 mg causes significant side effects on neuropsychological performance. Using a variety of neuropsychological tests, we found no significant differences after treatment with Δ⁹-THC compared to placebo treatment in verbal and visual memory, reaction time, intelligence, sustained attention, divided attention, vigilance, or mood. Only when using the Symptom Checklist 90-R (SCL-90-R) did our data provide evidence for a deterioration of obsessive-compulsive behavior (OCB) and a trend towards an increase in phobic anxiety. However, these results should be interpreted with caution as SCL-90-R has known limitations on measuring OCB. We suggest that the increase in phobic anxiety is mainly due to the fact that a single-dose treatment rules out the possibility of administering the dosage slowly. In contrast to results obtained from healthy marijuana users, a single-dose treatment with Δ⁹-THC in patients suffering from TS does not cause cognitive impairment. We therefore suggest that further investigations should concentrate on the effects of a longer-term therapy of TS with Δ⁹-THC.

Full Text

References

1 Arnold W. Der Pauli-Test. Berlin; Springer 1975
2 Benton A L. A visual retention test for clinical use. Arch Neurol Psychol. 1945; 59 273-291
3 Block R I, Farinpour R, Braverman K. Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. Pharmacol Biochem Behav. 1992; 43 907-917
4 Block R I, Ghoneim M M. Effects of chronic marijuana use on human cognition. Psychopharmacology (Berl.). 1993; 110 219-228
5 Brito G N O. A neurobiological model for Tourette syndrome centered on the nucleus accumbens. Med Hypothesis. 1997; 49 133-142
6 Chan P K, Chan S C, Yung W H. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurons by cannabinoid agonist. Neuroreport. 1998; 9 671-675
7 Clifford D B. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol. 1983; 13 669-671
8 Comings D E, Comings B G. Comorbid behavioral disorders. In: Kurlan R (ed.) Handbook of Tourette Syndrome and related tic and behavioral disorders. New York, Basel, Hong Kong; Marcel Dekker, Inc. 1993: 111-147
9 Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol. 1997; 38 44-48
10 Consroe P, Sandyk R, Snider S R. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci. 1986; 30 277-282
11 Crawley J N, Corwin R L, Robinson J K, Felder C C, Devane W A, Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav. 1993; 46 967-972
12 Derogatis L R, Lipman R S, Covi L. SCL-90: an outpatient psychiatric rating scale - preliminary report. Psychopharmacol Bull. 1973; 9 13-28
13 Derogatis L R. SCL 90. Administration, scoring and procedures. Manual-I for the R(evised) version and other instruments of the psychopathology rating scale series. John Hopkins University School of Medicine 1977
14 Devane W A, Hanus L, Breuer A, Pertwee R G, Stevenson L A, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258 1946-1949
15 Emrich H M, Leweke F M, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav. 1997; 56 803-807
16 Gessa G L, Melis M, Muntoni A L, Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol. 1998; 341 39-44
17 Golden G S. Psychologic and neuropsychologic aspects of Tourette Syndrome. Neurologic Clin. 1984; 2 91-102
18 Gorriti M A, Rodriguez de Fonseca F, Navarro M, Palomo T. Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol. 1999; 365 133-142
19 Grotenhermen F, Karus M. Marihuana: Die rechtliche Situation in Deutschland. Der Stand der medizinischen Forschung. In Marihuana, die verbotene Medizin. Zweitausendeins, Frankfurt am Main 1994 1. Aufl: 211-272
20 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23 56-62
21 Hamilton M. Development of rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967; 6 278-296
22 Hampson R E, Deadwyler S A. Role of cannabinoid receptors in memory storage. Neurobiol Dis. 1998; 5 474-482
23 Helmstadter C, Durwen H F. VLMT. Verbaler Lern- und Merkfähigkeitstest. Schweiz Arch Neurol Psychiatr. 1990; 141 21-30
24 Hemming M, Yellowlees P M. Effective treatment of Tourette Syndrome with marijuana. J Psychopharmacol. 1993; 7 389-391
25 Herkenham M, Lynn A B, Little M D, Johnson M R, Melvin L S, de Costa B R, Rice K C. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990; 87 1932-1936
26 Hill M, Armitage P. The two period cross-over clinical trial. Br J Clin Pharmacol. 1979; 8 7-20
27 Hollister L E. Health aspects of cannabis. Pharmacol Rev. 1986; 38 1-20
28 Jentsch J D, Andrusiak E, Tran A, Bowers M B, Roth R H. Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology. 1997; 16 426-432
29 Johannes S, Weber A, Müller-Vahl K R, Kolbe H, Dengler R, Münte T F. Event-related brain potentials show changed attentional mechanisms in Gilles de la Tourette syndrome. Eur J Neurology. 1997; 4 152-161
30 Kim S W, Dysken M W, Kuskowski M. The Symptom Checklist-90: Obsessive-Compulsive Subscale: A reliability and validity study. Psychiatry Res. 1992; 41 37-44
31 Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol Pharm Bull. 1998; 21 224-226
32 Kleiber D, Kovar K-A. Psychische und soziale Konsequenzen des Cannabiskonsums. In: Kleiber D, Kovar K-A (ed.) Auswirkungen des Cannabiskonsums: eine Expertise zu pharmakologischen und psychosozialen Konsequenzen. Stuttgart; Wissenschaftliche Verlagsgesellschaft mbH 1998: 88-225
33 Korzyn A D. Future therapies. In: Kurlan R (ed.) Handbook of Tourette Syndrome and related tic and behavioral disorders. New York, Basel, Hong Kong; Marcel Dekker, Inc 1993: 199-220
34 Leckman J F, Towbin K E, Ort S I, Cohen D J. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF Tourette Syndrome and tic disorders. New York; John Wiley 1988: 55-78
35 Mailleux P, Vanderhaeghen J-J. Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci Lett. 1992; 148 173-176
36 Maneuf Y P, Nash J E, Crossman A R, Brotchie J M. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol. 1996; 308 161-164
37 Marsden C D. Treatment of torsion dystonia. Barbeau, A. (ed.) Disorders of Movement. Current status of modern therapy. Philadelphia; Lippincott 1981 8: 81-104
38 Merz J, Lehrl S, Galster J V, Erzigkeit H. MWT-B - ein Intelligenzkurztest. Psychiatr Neurol Med Psychol. 1975; 27 423-428
39 Miller A S, Sanudo-Pena M C, Walker J M. Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus. Brain Res. 1998; 793 7-11
40 Miller A S, Walker J M. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. Eur J Pharmacol. 1995; 279 179-185
41 Molina-Holgado F, Amaro A, Gonzalez M I, Alvarez F J, Leret M L. Effect of maternal delta 9-tetrahydrocannabinol on developing serotonergic system. Eur J Pharmacol. 1996; 316 39-42
42 Müller-Vahl K R, Kolbe H, Schneider U, Emrich H M. Cannabinoids: Possible role in pathophysiology of Gilles de la Tourette-syndrome. Acta Psychiat Scand. 1998; 98 502-506
43 Müller-Vahl K R, Schneider U, Koblenz A, Jöbges M, Kolbe H, Dahltrup T, Emrich H M. Treatment of Tourette-Syndrome with delta-9-Tetrahydrocannabinol (THC): a randomized crossover trial. (submitted)
44 Müller-Vahl K R, Schneider U, Kolbe H, Emrich H M. Treatment of Tourette-Syndrome with delta-9-Tetrahydrocannabinol. Am J Psychiatry. 1999; 156 495
45 Palumbo D, Maughan A, Kurlan R. Hypothesis III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome. Arch Neurol. 1997; 54 475-483
46 Pope H G, Gruber A J, Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend. 1995; 38 25-34
47 Pope H G, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA. 1996; 275 521-527
48 Sandyk R, Awerbuch G. Marijuana and Tourette Syndrome. J Clin Psychopharmacol. 1988; 8 444-445
49 Sandyk R, Snider S R, Consroe P, Elias S M. Cannabidiol in dystonic movement disorders. Psychiatry Res. 1986; 18 291
50 Sanudo-Pena M C, Walker J M. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J Neurophysiol. 1997; 77 1635-1638
51 Schneider U, Leweke F M, Müller-Vahl K R, Emrich H M. Cannabinoid/anandamide system and schizophrenia: is there evidence for association?. Pharmacopsychiatry. 1998; 31 (Suppl. 2) 110-113
52 Schwartz R H, Gruenewald P J, Klitzner M, Fedio P. Short-term memory impairment in cannabis-dependent adolescents. Am J Dis Child. 1989; 143 1214-1219
53 Shapiro A K, Shapiro E, Young J G, Feinberg T E. Gilles de la Tourette Syndrome. Raven Press, New York 2d ed 1988
54 Shen M, Piser T M, Seybold V S, Thayer S A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci. 1996; 16 4322-4334
55 Shen M, Thayer S A. Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol. 1999; 55 8-13
56 Sieradzan K A, Fox S H, Dick J, Brotchie J M. The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson's disease (PD). Mov Disord. 1998; 13 (Suppl. 2) 29
57 Solowij N, Michie P T, Fox A M. Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry. 1995; 37 731-739
58 Swets J A, Green D M, Getty D J, Swets J B. Signal detection and identification at successive stages of observation. Percept Psychopsy. 1978; 23 275-289
59 Varma V K, Malhotra A K, Dang R, Das K, Nehra R. Cannabis and cognitive functions: a prospective study. Drug Alcohol Depend. 1988; 21 147-152
60 Wechsler D. A standardized memory scale for clinical use. J Psychol. 1945; 19 87-95
61 Wechsler D. Die Messung der Intelligenz Erwachsener. Bern; Huber Verlag 1956
62 Weeks R A, Turjanski N, Brooks D J. Tourette Syndrome: a disorder of cingulate and orbitofrontal function?. QJM. 1996; 89 401-408
63 Woody S R, Steketee G, Chambless D L. The usefulness of the Obsessive Compulsive Scale of the Symptom Checklist-90-Revised. Behav Res Ther. 1995; 33 607-611
64 Yordanova J, Dumais-Huber C, Rothenberger A, Woerner W. Frontocortical activity in children with comorbidity of tic disorder and attention-deficit hyperactivity disorder. Biol Psychiatry. 1997; 41 585-594
65 Ziemann U, Paulus W, Rothenberger A. Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation. Am J Psychiatry. 1997; 154 1277-1284
66 Zimmermann P, Fimm B. Neuropsychologische Testbatterie zur Erfassung von Aufmerksamkeitsdefiziten. Psychologisches Institut der Universität Freiburg 1989

Dr. med. Kirsten R. Müller-Vahl

Department of Clinical Psychiatry and Psychotherapy
Medical School Hannover

Carl-Neuberg-Straße 1

30625 Hannover

Germany

Phone: +49-511-5323110

Fax: +49-511-5323115

Email: Mueller-Vahl.Kirsten@MH-Hannover.de